Live feed06:45:00·1504dPRReleasevia QuantisnowMerck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)ByQuantisnow·Wall Street's wire, on your screen.MRK· Merck & Company Inc.Health Care